title: [Attention deficit hyperactivity disorder with comorbid anxiety disorders: pharmacotherapy options].
abstract: Comorbid anxiety disorders are observed in many patients with attention deficit hyperactivity disorder (ADHD): 25-33% compared to 6-10% in pediatric population. Therapeutic effects of Adaptol have been studied, indicated for children and adolescents with ADHD as monotherapy, in dosages of 25-35 mg/kg for 1-3 months. The positive influence of Adaptol on the core symptoms of ADHD was confirmed: reduction of hyperactivity and impulsivity was registered after 1st month, while clinical manifestations of the attention deficit were decreased on the 2nd-3rd months of the treatment. Anxiolytic activity became apparent from the 1st month and continued to increase on the 2nd-3rd months of the treatment. Simultaneously significant reduction of the oppositional-defiant disorder manifestations were observed.
authors.forename: N N
authors.initials: NN
authors.lastname: Zavadenko
authors.forename: A A
authors.initials: AA
authors.lastname: Solomasova
mesh_terms: D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology*; D001736:Biureas / Q000627:therapeutic use*; D002648:Child; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D001736:Biureas; C015979:mebikar